TY - JOUR T1 - Atrial fibrillation in patients on haemodialysis in Andalusia. Prevalence, clinical profile and therapeutic management JO - Nefrología (English Edition) T2 - AU - Sánchez Perales,Carmen AU - Vázquez Sánchez,Teresa AU - Salas Bravo,Daniel AU - Ortega Anguiano,Sonia AU - Vázquez Ruiz de Castroviejo,Eduardo SN - 20132514 M3 - 10.1016/j.nefroe.2017.09.010 DO - 10.1016/j.nefroe.2017.09.010 UR - https://www.revistanefrologia.com/en-atrial-fibrillation-in-patients-on-articulo-S2013251418300166 AB - Atrial fibrillation (AF) represents an important social and healthcare problem. There is wide variability in the prevalence of this arrhythmia in studies analysing patients on haemodialysis (HD). ObjectiveTo investigate the prevalence, clinical profile and therapeutic management of patients with AF on HD in Andalusia. MethodsWe asked the public healthcare system of Andalusia to provide us with the number of patients who were being treated with HD. We asked attending nephrologists from all hospital and outpatient centers in 5 of the 8 Andalusian provinces to perform an electrocardiogram and to fill out a questionnaire on patients selected by simple random sampling. ResultsA total of 2348 patients were being treated with HD in the 5 provinces included in the study. The estimated sample size was 285 patients. We obtained an electrocardiogram and information from 252 patients (88.4%); mean age 65.3±16 years; 40.9% women. Sixty-three patients (25%) had AF. Of these, 36 (14.3%) had AF in the recorded ECG and in the rest it had been documented previously. In the multivariate analysis, older age (OR: 1.071; 95% CI: 1.036–1.107; p=0.000) and greater time on HD (OR: 1.009; 95% CI: 1.004–1.014; p=0.000) were independently associated with the presence of AF. Of the patients with AF, 41.3% were on anticoagulant treatment at the time of the study; and 41.2% were on antiplatelet agents. ConclusionsAF in dialysis units is an important finding. Establishing the risk–benefit ratio of anticoagulant treatment constitutes a real challenge. Well-designed clinical trials are pivotal in order to define the rational use of antithrombotic drugs. ER -